Biotech News
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
ir.foghorntx.com2026-05-06 15:04 EST
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+